Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
This is a comparative study to investigate the safety and efficacy of fidaxomicin versus
 vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
The primary objective of this pivotal study is to investigate the safety and efficacy of
 fidaxomicin versus vancomycin in subjects with Clostridium difficile-associated diarrhea
 (CDAD). The cure rates at end of therapy and recurrence rates will be evaluated and compared.
Inclusion Criteria:

 -  Males/females with CDAD

 -  Females must use adequate contraception

 -  Signed informed consent

 Exclusion Criteria:

 -  Life-threatening CDAD

 -  Toxic megacolon

 -  Pregnant

 -  Concurrent use of diarrheal agents

 -  Participation in other trials